A biocompatible particle to detect and confirm molecules reactive against the peptide/HLA complex and HLA class I/II molecules

Technology #d-1086

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Image Gallery
Categories
Researchers
Jon Weidanz, Ph.D.
Dr. Weidanz has over 20 years of experience in biotechnology research with emphasis in immunology, immunotherapy and immunodiagnostic product development, especially as these disciplines relate to oncology and the development of products to diagnose and treat cancer. His work has been funded from the NIH, DOD and American Heart Association. He is the founder and Chief Scientific Officer of Receptor Logic, Inc., and most recently served as its President. His other duties include serving as: 1) Chairman for the Department of Immunotherapeutics and Biotechnology, 2) Director for the Center for Immunotherapeutic Research and Product Development, and 3) a tenured Professor at Texas Tech University Health Sciences Center (TTUHSC). He received the President's Excellence in Teaching Award as well as the Chancellor's Council Distinguished Teaching Award for his innovative classroom instruction TTUHSC.
External Link (www.ttuhsc.edu)
Devin Lowe, Ph.D.
Oriana Hawkins
Managed By
David McClure
Director Licensing 806-834-5899
Patent Protection

PARTICLE TO DETECT AND CONFIRM MONOCLONAL AGENTS REACTIVE AGAINST THE PEPTIDE/HUMAN LEUKOCYTE ANTIGEN (HLA) CLASS I/II COMPLEX AND HLA CLASS I/II MOLECULES FOR THE DEVELOPMENT OF THERAPEUTICS

Provisional Patent Application Filed

The human leukocyte antigen (HLA) is composed of class I and II complexes, which are expressed by nucleated cells in the body. The HLA class system uses specific peptides in order to inform the immune system of the cell's health status. In the case of an abnormal event (e.g., cancer), immunologically-related molecules such as antibodies or lymphocytes bind their cognate HLA-derived peptide and induce the death of the cell through a number of possible effector mechanisms in order to maintain the integrity of the host. 
 
This technology consists of a polylactic-co-glycolic acid particle in the nanometer-micrometer size range with specific peptide/HLA multimers tethered to its outer surface via a PEG linker group, resulting in the particle designated NP-HLA. This NP-HLA particle represents a useful tool to detect molecules with specific reactivity against the peptide/HLA complex or HLA class I/II molecules in biologically relevant solutions such as cell culture media, sera, and buffered liquids (e.g. PBS) for confirmatory, diagnostic, and therapeutic purposes. Overall, the NP-HLA particle is biocompatible, stable, and exhibits intra/inter-assay precision and linearity in detecting specific target binding. The invention represents an alternative format to detect and characterize specific molecular interactions between the peptide/HLA complex or HLA class I/II molecules. This invention can also be utilized as an immune staining reagent.
 
Market Applications:

  • Immunoassays
  • Possible use in pharmacokinetic/pharmacodynamics studies
  • Possible use to determine transplantation suitability
  • Immune staining reagent

 
Features, Benefits and Advantages:

  • Less time to detect/characterize interactions
  • Greater inter-assay and inter-operator precision

 
Intellectual Property:
A provisional application with the serial number 62/144,427 was filed on April 8, 2015.
 
Development Stage:
Work on the invention is still continuing.